Coronary Stents Market Anticipates Steady 4.35% CAGR Through 2030

Coronary Stents Market Overview

“The Coronary Stents Market is estimated to increase at a CAGR of 4.35% from $ 11.45 billion in 2023 to $ 18.56 billion by 2030.”

Coronary stenting is recommended for patients with obstructed coronary arteries, with angioplasty being the primary treatment for severe blockages. The number of stenting patients has been increasing over the past decade, with outpatient stenting reducing hospitalization requirements. Bio-absorbable coronary scaffolds are superior to drug-eluting stents for treating coronary blockage. Stenting procedures improve blood flow, prevent further heart muscle damage, and reduce medication use by easing symptoms like angina and shortness of breath.

The demand for portable and fixed coronary stents is expected to rise exponentially in the coming years due to an aging population and an increase in risk factors like cardiovascular diseases, complicated lesions, diabetes, and obesity. Stenting treatments offer benefits such as increased blood flow, avoiding heart muscle deterioration, and easing heart disease symptoms like angina and shortness of breath, reducing the need for coronary bypass surgery. This less invasive approach is preferred by surgeons.

Obesity is a major global risk factor for cardiovascular diseases, leading to excessive fat buildup in the artery lumen, causing coronary heart disease. Controlling obesity and losing weight are crucial for preventing cardiovascular disease. The coronary stents market is expected to be significantly impacted by these prospects, as new companies focus on innovation and funding for R&D initiatives.

>>>Download Sample Report Now: https://marketreportservice.com/request-sample/coronary-stents-market-54493

Coronary Stents Market Segment Analysis

The drug-eluting stent segment is expected to dominate the market over the forecast period. These stents, consisting of a metallic stent, a polymer coating, and an antirestenotic drug, are preferred over bare-metal stents for percutaneous coronary intervention due to their reduced risk of target vessel revascularization. The three most popular drug-eluting stent systems are Cre8 EVO from Boston Scientific, Abbott's XIENCE, and SYNERGY DES, which are expected to contribute significantly to their expansion.

The prevalence of diabetes and the elderly in South-East Asia has increased the risk of coronary heart disease. In 2021, the region had over 90 million individuals with diabetes, with 151 million expected by 2045. 51.3% of those with diabetes are undiagnosed. As diabetes incidence increases, cardiovascular disease will also rise, increasing the need for drug-eluting stents.

The self-expandable and balloon expandable coronary stent market is expected to dominate due to their clinical efficacy and the emergence of local and regional producers. These stents are particularly effective in treating acute myocardial infarction and closely track arterial expansion. Segmental growth is expected to be fueled by their clinical effectiveness. The balloon expandable category is expected to see steady growth due to increased research into technologically improved medical stents and rising heart problem frequency.

Market Dynamics

Drivers

The aging population is leading to a growing patient population with serious cardiovascular disorders, with hypertension becoming a significant public health issue. Older people are more susceptible to cardiovascular illnesses due to higher total blood cholesterol levels. Obesity is a significant risk factor for many cardiovascular disorders, as it leads to abnormal fat buildup in the artery lumen, potentially causing coronary heart disease and other health issues. Therefore, managing obesity and losing weight is crucial for preventing cardiovascular disease.

Stenting operations are increasing due to their benefits, such as increased blood flow and preventing further heart muscle deterioration. They are recommended for patients with blocked coronary arteries, with angioplasty being the primary treatment for severe blockages. Over the past decade, there has been a steady increase in stenting procedures due to shorter hospital stays and outpatient treatments. Bio absorbable coronary scaffolds have been found to be more advantageous than drug-eluting stents for treating coronary blockage.

Restraints

Increasing the quantity of stenting operations to boost sales

Additional benefits of stenting treatments include a significant increase in blood flow and the avoidance of additional heart muscle deterioration. Coronary stenting is recommended to patients who have blocked coronary arteries. For individuals with severe acute coronary artery blockages, angioplasty is the primary line of therapy. Over the past 10 years, there has been a steady rise in the number of patients having stenting procedures. This is because short hospital stays are becoming more common because to outpatient coronary stenting treatments. Additionally, it has been found that the use of bio absorbable coronary scaffolds in coronary blockage is more advantageous than the use of drug-eluting stents.

Competitive Landscape of the Coronary Stents Market Analysis

• Abbott Laboratories Inc.
• Boston Scientific Corporation
• Medtronic Inc.
• Terumo Corporation
• Braun Melsungen AG
• R. Bard Inc.
• Cook Medical Inc.
• Biotronik SE & Co. KG
• MicroPort Scientific Corporation

New Developments in Coronary Stents Market

In April 2023, Terumo Europe N.V., the European arm of a leading Japanese medical device company, announced the start of its new clinical study for a coronary stent system, which received a CE mark approval in November 2022. The study explores the use of Ultimaster Nagomi™ sirolimus eluting coronary stent system in complex PCI patients.

In February 2023, Olympus, a leading Japanese medical device manufacturer, announced that it had acquired Taewoong Medical, a stent maker based in South Korea at US$ 370 million. This deal is the result of Olympus’ efforts to expand its medical device offerings and expand its revenue generation potential.

In August 2022, Medtronic, a renowned name in the global medical technology space, announced the launch of its new drug-eluting stent. The Onyx Frontier was branded as the most deliverable DES owing to its updated design and improved flexibility.

Regional Analysis of Global Coronary Stents Industry

“China is a crucial market for Coronary Stent Manufacturers due to its high demand and high production capacity.”

China is predicted to experience a larger CAGR in coronary stent demand over the next decade due to factors such as sedentary lifestyles, unhealthy eating habits, and an increasing elderly population. The rise in stent implantation procedures and increased use of coronary stents is expected to drive sales. Long-term market development is supported by rising healthcare spending from both public and private sectors, and ongoing clinical trials in China are driving the development of new, efficient, and secure medicines.

“The United States is a lucrative market for Coronary Stent producers due to its high production volume and high demand.”

The US coronary stent market is expected to grow due to the increasing prevalence of cardiovascular illnesses and the elderly population. Coronary artery diseases account for 1 in 4 fatalities in the US, with 785,000 people experiencing their first heart attack and 470,000 suffering from myocardial infarction. The opening of specialized clinics and increased investments in coronary stent advancements are also contributing to the growth. The presence of significant US coronary stent producers also boosts growth.

Segments Covered in the Coronary Stents Market Report

By Product:

• Bare Metal Stents
• Drug Eluting Stents
• Bio-absorbable Stents

By Region:

• North America
• Latin America
• Europe
• APAC
• MEA

Frequently Asked Questions

What is the expected growth rate of the Coronary Stents market over the next 7 years?

Coronary Stents Market is estimated to increase at a CAGR of 4.35% from $ 11.45 billion in 2023 to $ 18.56 billion by 2030 | Report 2023 by published by Market Report Service.

Who are the major players in the Coronary Stents market and what is their market share?

Abbott Laboratories Inc., Boston Scientific Corporation, Medtronic Inc., Terumo Corporation, B. Braun Melsungen AG, C. R. Bard Inc., Cook Medical Inc., Biotronik SE & Co. KG, MicroPort Scientific Corporation, are prominent players operating and dominating in the market.

Who are the top 3 Coronary Stents Market Key Vendors?

Abbott Laboratories Inc., Boston Scientific Corporation, Medtronic Inc, are key players in the Coronary Stents market.

Which geographical areas dominate the worldwide market for Coronary Stents?

North America region are emerging as the top regional markets for Coronary Stents solutions.